Terns has a modest market cap of less than $800 million, and its possible upside could be massive.Goldman Sachs projects that the anti-obesity market will be worth as much as$100 billion by the end of the decade. It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The best-selling glucagon-like peptide-1 (GLP-1) weight-loss treatments today are injections, but companies are working on pills which could be more attractive to patients, esp ...